Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer. Issue 5 (September 2019)

• Record Type: Journal Article
• Authors: Karuturi, Meghan S.; Holmes, Holly M.; Lei, Xiudong; Johnson, Michael; Barcenas, Carlos H.; Cantor, Scott B.; Gallick, Gary E.; Bast, Robert C.; Giordano, Sharon H.
• Is Part Of: Journal of geriatric oncology. Volume 10:Issue 5(2019)
• Page Start: 705
• Page End: 708
• Publication Date: 2019-09
• Subjects: Geriatric oncology -- Health outcomes -- Breast cancer -- Colorectal cancer -- Polypharmacy -- Inappropriate medications -- STOPP criteria; Geriatric oncology -- Periodicals; Neoplasms -- Periodicals; Aged -- Periodicals; Geriatric oncology; Electronic journals; Periodicals; 618.976994005
• DOI: 10.1016/j.jgo.2019.01.024
• Languages: English
• ISSNs: 1879-4068

Abstract

Abstract: Purpose: Screening for potentially inappropriate medications (PIM) is recommended in older patients with cancer receiving chemotherapy, given the concern for adverse drug reactions, drug-drug interactions and non-adherence. Our objective was to determine the impact of PIM on outcomes in patients with breast and colorectal cancers receiving chemotherapy. Methods: We used data from the SEER-Medicare database, including patients >/= 66 years old with a diagnosis of Stage II/III breast and colorectal cancer made between 7/1/2007–12/31/2009. We used modified STOPP criteria to define baseline PIM as a dichotomous variable in the 4 months prior to diagnosis. STOPP criteria was used based on its performance as a robust measure of PIM. Outcomes measures included ER visits, hospitalizations, and death within 3 months from the last chemotherapy, and a composite of the three. We used Chi-square or Fisher's exact test to determine associations of PIM with covariates and outcomes, and Cox proportional hazards (PH) model for the time-to-event analysis. Results: Final analysis included 1, 595 patients with breast cancer and 1, 528 patients with colorectal cancer. Frequency of baseline PIM by STOPP was 31.5% in the breast and 30.9% in the colorectal cohort. In the breast cohort, associations with the composite outcome in the Cox PH model included disease stage, comorbidity, medication number and baseline ER visits/hospitalization. Age, gender, race, comorbidity and baseline ER visits/hospitalization were associated in the colorectal cohort. PIM was not associated with outcomes in either cohort, aside from hospitalization in the breast. Conclusions: We found no consistent association between pre-chemotherapy PIM defined by STOPP and outcomes.